Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad ...

In the early twentieth century, a tumor-causing virus called the Rous sarcoma virus ... Cancer cells heavily rely on oncogenic mutations for their growth, proliferation, and survival.

This discovery is the first step toward identifying potential therapeutic targets along the pathway. “This is a very powerful oncogenic pathway set off by MYC activation,” says Srinivasan ...

China Objective Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), mostly characterised by HBV integrations, is prevalent worldwide. Previous HBV studies mainly focused on a few hotspot ...

Researchers collected tissue and blood samples from family members, but tests didn’t detect any viruses. As unusual as the Kiliuses ... of neoplastic [tumorous] diseases in which hereditary or ...

These recombinant viruses were used to infect C33A cells to achieve sustained ... This study lays the foundation for further exploration of the oncogenic mechanisms of HPV E6/E7 and may provide new ...

Philippine Infectious Diseases Society for Obstetrics and Gynecology vice president Martha Millar-Aquino said boys can also benefit from vaccination against human papilloma virus because they ... one ...

Virus-containing supernatants were harvested 48 hours post-transfection, filtered through a 0.45 µm pore size filter, and used for transducing target HCT116 and U2OS cells in the presence of 8 µg/ml ...